OncoSec's Punit Dhillon Named "Most Admired CEO" by San Diego Business Journal
SAN DIEGO, Feb. 19, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that Chief Executive Officer Punit Dhillon received the honor of being named "2016 Most Admired CEO" by the San Diego Business Journal in the Small Public Company category.
Mr. Dhillon, who co-founded OncoSec in 2011, was recognized for his leadership and contributions to the Company's growth, achievements, and innovation in the field of cancer immunotherapy. Over the past year, OncoSec has developed a state-of-the-art technology platform, fostered an employee culture aligned with the Company's values, and focused its clinical pipeline to address one of the greatest challenges in oncology today. OncoSec also fulfilled a key corporate development goal by listing its common stock on The NASDAQ Stock Market LLC.
"It's an honor for OncoSec to be recognized by the San Diego Business Journal and alongside several distinguished leaders who are making a meaningful impact in our city," said Mr. Dhillon. "I'm pleased to represent OncoSec on behalf of our entire team and thank our dedicated employees, investors, and fellow associates who have supported the Company's mission to deliver safer and more effective treatments for patients in the fight against cancer."
The San Diego Business Journal's 2016 Most Admired CEO Awards recognizes local industry leaders' achievements within their companies and in the community. The winners and finalists are lauded for demonstrating determination and insight yielding successes for their organizations. Nominees were judged in the categories of nonprofit organization, business nonprofit, education, family-owned business, government agency, privately held company, and public company.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
OncoSec Medical Incorporated
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosecs-punit-dhillon-named-most-admired-ceo-by-san-diego-business-journal-300223049.html
SOURCE OncoSec Medical Incorporated